Literature DB >> 22562451

Assessment of the interface between retroperitoneal fat infiltration of pancreatic ductal carcinoma and the major artery by multidetector-row computed tomography: surgical outcomes and correlation with histopathological extension.

Yusuke Yamamoto1, Kazuaki Shimada, Yoshito Takeuchi, Keitaro Sofue, Kentaro Shibamoto, Satoshi Nara, Minoru Esaki, Yoshihiro Sakamoto, Tomoo Kosuge, Nobuyoshi Hiraoka.   

Abstract

BACKGROUND: Precise assessment of retroperitoneal invasion is clinically important to allow the achievement of negative margin resections.
METHODS: The clinical records of 132 patients who underwent macroscopic curative pancreaticoduodenectomy for invasive ductal carcinoma of the pancreas between 2004 and 2008 were retrospectively examined. The clinicopathological factors, including retroperitoneal fat infiltration classified into four groups by multidetector-row computed tomography (MDCT), were analyzed. The relationship between the grade of retroperitoneal fat infiltration and surgical outcomes, as well as various histopathological factors, was also investigated.
RESULTS: The 5 year survival rate was 55.6 % for grade 0 infiltration (n = 8), 38.7 % for grade 1 (n = 54), 16.4 % for grade 2 (n = 49), and 0 % for grade 3 (n = 21). There were significant differences in survival in each group. Extrapancreatic nerve invasion and the surgical margin status were significantly associated with retroperitoneal fat infiltration demonstrated on MDCT. According to the grading classification among the 43 patients with pathological portal vein invasion, the 5 year survival rate was 45.9 % for patients with grade 1, which was significantly better survival that those with grade 2 (P = 0.007).
CONCLUSION: The grading criteria for retroperitoneal fat infiltration may be useful as a predictor of survival after pancreaticoduodenectomy for pancreatic head carcinoma. Pancreaticoduodenectomy with portal vein resection could provide favorable survival in patients with grade 1 retroperitoneal fat infiltration, even if histopathological portal vein invasion is present.

Entities:  

Mesh:

Year:  2012        PMID: 22562451     DOI: 10.1007/s00268-012-1618-9

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  27 in total

1.  1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience.

Authors:  Jordan M Winter; John L Cameron; Kurtis A Campbell; Meghan A Arnold; David C Chang; Joann Coleman; Mary B Hodgin; Patricia K Sauter; Ralph H Hruban; Taylor S Riall; Richard D Schulick; Michael A Choti; Keith D Lillemoe; Charles J Yeo
Journal:  J Gastrointest Surg       Date:  2006-11       Impact factor: 3.452

2.  Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement.

Authors:  Ross A Abrams; Andrew M Lowy; Eileen M O'Reilly; Robert A Wolff; Vincent J Picozzi; Peter W T Pisters
Journal:  Ann Surg Oncol       Date:  2009-04-24       Impact factor: 5.344

3.  Redefining resection margin status in pancreatic cancer.

Authors:  Caroline S Verbeke; Krishna V Menon
Journal:  HPB (Oxford)       Date:  2009-06       Impact factor: 3.647

4.  Multidetector CT in the evaluation of retroperitoneal fat tissue infiltration in ductal adenocarcinoma of the pancreatic head: correlation with histopathological findings.

Authors:  Salvatore Mazzeo; Carla Cappelli; Valentina Battaglia; Davide Caramella; Gabriele Caproni; Benedetta Pontillo Contillo; Marco Del Chiaro; Ugo Boggi; Niccola Funel; Luca Pollina; Daniela Campani; Franco Mosca; Carlo Bartolozzi
Journal:  Abdom Imaging       Date:  2009-07-18

5.  MDCT findings of extrapancreatic nerve plexus invasion by pancreas head carcinoma: correlation with en bloc pathological specimens and diagnostic accuracy.

Authors:  Kentaro Mochizuki; Toshifumi Gabata; Kazuto Kozaka; Yuki Hattori; Yoh Zen; Hirohisa Kitagawa; Masato Kayahara; Tetsuo Ohta; Osamu Matsui
Journal:  Eur Radiol       Date:  2010-02-10       Impact factor: 5.315

6.  Clinical implications of combined portal vein resection as a palliative procedure in patients undergoing pancreaticoduodenectomy for pancreatic head carcinoma.

Authors:  Kazuaki Shimada; Tsuyoshi Sano; Yoshihiro Sakamoto; Tomoo Kosuge
Journal:  Ann Surg Oncol       Date:  2006-12       Impact factor: 5.344

7.  Vascular involvement in pancreatic adenocarcinoma: reassessment by thin-section CT.

Authors:  E M Loyer; C L David; R A Dubrow; D B Evans; C Charnsangavej
Journal:  Abdom Imaging       Date:  1996 May-Jun

8.  Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience.

Authors:  Axel Richter; Marco Niedergethmann; Jörg W Sturm; Dietmar Lorenz; Stefan Post; Michael Trede
Journal:  World J Surg       Date:  2003-02-27       Impact factor: 3.352

9.  Pancreatic malignancy: value of arterial, pancreatic, and hepatic phase imaging with multi-detector row CT.

Authors:  Joel G Fletcher; Maurits J Wiersema; Michael A Farrell; Jeff L Fidler; Lawrence J Burgart; Takashi Koyama; C Daniel Johnson; David H Stephens; Ellen M Ward; W Scott Harmsen
Journal:  Radiology       Date:  2003-10       Impact factor: 11.105

10.  Pancreatic Cancer Registry in Japan: 20 years of experience.

Authors:  Seiki Matsuno; Shinichi Egawa; Shoji Fukuyama; Fuyuhiko Motoi; Makoto Sunamura; Shuji Isaji; Toshihide Imaizumi; Shuichi Okada; Hiroyuki Kato; Kouichi Suda; Akimasa Nakao; Takehisa Hiraoka; Ryo Hosotani; Kazunori Takeda
Journal:  Pancreas       Date:  2004-04       Impact factor: 3.327

View more
  1 in total

1.  Plasma microRNA profiles: identification of miR-744 as a novel diagnostic and prognostic biomarker in pancreatic cancer.

Authors:  Mahito Miyamae; Shuhei Komatsu; Daisuke Ichikawa; Tsutomu Kawaguchi; Shoji Hirajima; Wataru Okajima; Takuma Ohashi; Taisuke Imamura; Hirotaka Konishi; Atsushi Shiozaki; Ryo Morimura; Hisashi Ikoma; Toshiya Ochiai; Kazuma Okamoto; Hiroki Taniguchi; Eigo Otsuji
Journal:  Br J Cancer       Date:  2015-10-27       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.